Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

the safety and

tolerability results of ITMN-191 were excellent.

-- That the trial had achieved its principal goals for viral kinetic

performance, safety and tolerability to advance the program into a

triple combination study with Pegasys(R) and ribavirin.

-- It expected to complete enrollment of the third dose cohort in the

MAD study in January 2008. InterMune announced today that

enrollment of that cohort was completed in late January and that

data from the third cohort are not yet available to the company.

-- InterMune expects to begin a 14-day triple combination study of

ITMN-191 with Pegasys(R) and ribavirin in the second quarter of


Guidance for 2008 Operating Expenses

InterMune today provided its forward-looking guidance with respect to operating expenses in 2008.

For the year ending December 31, 2008, R&D expense is anticipated to be similar to 2007 in a range of approximately $100 to $110 million, net of development cost reimbursements under the Roche collaboration. G&A expense is anticipated to be in a range of approximately $25 to $30 million.

Key Development Program Milestones

InterMune today noted the upcoming milestones with respect to its key development programs.

CAPACITY Program in IPF:

-- InterMune expects to announce top-line results of its Phase 3 CAPACITY

program in IPF in January of 2009.

ITMN-191 Program in HCV:

-- In conjunction with its partner, Roche, InterMune has decided to

complete a fourth cohort of the Phase 1b multiple-ascending-dose (MAD)

study to further inform the planned 14-day triple therapy study and

potential direct anti-viral combination studies in the future.

Consequently, InterMune has decided to announce results from the first

four cohorts of the Phase lb MAD study

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Today, DuPont and Caribou ... genome editing, jointly announced a strategic alliance. As ... their respective patent portfolios, with DuPont receiving exclusive ... major row crops, and non-exclusive rights in other ... --> --> In addition, ...
(Date:10/8/2015)... ... 2015 , ... Talon Innovations, a provider of Precision Machined Products ... it is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in ... Talon Innovations was recognized as a nominee for this competitive award. , The ...
(Date:10/7/2015)... ... ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells and Their Secretions ... 4:30 pm. , Dr. Riordan is one of the early pioneers and leading experts ... Chief Science Officer of the Riordan-McKenna Institute of Regenerative Orthopedics in Southlake, ...
(Date:10/7/2015)... , Oct. 7, 2015  October is National Liver Awareness ... committed to donating a portion of its October profits ... hepatology practices. ... a variety of ways; whether it is by providing ... collaborating with researchers in different disease and investigation areas, ...
Breaking Biology Technology:
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... a clinical trial using intravenous administration of,REOLYSIN(R) ... well as immune modulator, in patients with ... Spicer of King,s College in London,Dr. Johann ...
... (Nasdaq:,ATSI), manufacturer and marketer of state-of-the-art cardiac surgery,products, ... Rodman & Renshaw,5th Annual Global Healthcare Conference at ... on Tuesday, May 20, 2008. Michael Dale, President ... a.m. local time., (Logo: ), ...
... Inc. (OTC,Bulletin Board: PLMO) announced today that it ... taking its total holdings to 61% in this ... for pulmonary,related medical conditions., Pulmo BioTech CEO ... technology, developed and owned by PulmoScience, will dominate ...
Cached Biology Technology:
(Date:9/30/2015)... 30, 2015  With nearly 300,000 Americans living with ... SCIs estimated to reach 12,500 annually, the role of ... Services for Independent Living (SCRS-IL) is increasingly important. ... California opening doors to independence for individuals ... services, notably assistive technology services and education. ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
Breaking Biology News(10 mins):
... nice piece of certified sustainable fish at the supermarket, you,d ... aren,t always what they seem, according to researchers who have ... report their findings in the August 23 issue of ... found that, for fish purchased in US groceries, not all ...
... 2011, 3:00 PM U.S. EASTERN TIME) A study ... Sciences (PNAS) documents the success of a Wildlife ... to improve rural livelihoods while restoring local wildlife populations., ... began in Zambia in 2003 and has resulted in ...
... Research (ONR) will share partnership possibilities with members of ... Gold Coast Small Business Opportunity Conference, being held Aug. ... to identify potential program participants from among the 1,500 ... Small Business Programs. "The event is a great way ...
Cached Biology News:
... of the smallest thermal cyclers on the market, ... the 0.5ml (20 samples) or 0.2ml microtube (25 ... heating and cooling rate of 3.6C/sec and 2.0C/sec ... Fast track programming with new quick dial ...
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: